If members of Congress are sincere in their call to thoughtfully consider drug pricing, they should acknowledge that Mr. Shkreli and his unorthodox approach to pharmaceuticals are an anomaly (in every sense of the word).
While Mr. Shkreli’s theatrics garnered the media circus, a more erudite debate on drug pricing is fortunately taking shape in the upper body where Sen. Orrin Hatch, Utah Republican, and Sen. Elizabeth Warren, Massachusetts Democrat, present stark differences on how to tackle drug prices.
Read Full Article »